I guess I brought some good vibes back from my vacation. I still would say that we are not ever close to saying that an uptrend is in play but these strong days are the necessary condition to start that trend. We are at a level where additional upside gets us starting to think more […]
June 7th Biotech Update
I am back from my little vacation and have some catching up to do. The sector seems to be looking for direction as it bounced around from my perspective. I did not follow its movements closely but from the distance of the beach it looks as if the sector has not made a decision to […]
May 3rd Biotech Update
So we had a late day rally yesterday and I am not sure what to think about it. I sort of prefer the weak Monday and gap down Tuesday morning to reverse green sort of setups. It was nice to see the sector rally on what was a group of bad news but with […]
April 29th Biotech Update
We remain stuck in that I think the sector is gong to move with the broader market and the broader market is not good at this point. I would think both the sector and broader market were oversold in the short term and due for at least a dead cat bounce and yesterday looked to […]
April 13th Biotech Update
We had a chance to build some nice momentum and yet we failed once again. To be fair the broader markets have not been that conducive so it is not as if this is a sector specific move but it is yet another disappointment in a long line of disappointments. The sector can still save […]
April 7th Biotech Update
It has been an up and down week and while some of the moves felt trend like, i.e. that they would be part of a more sustained move to the upside or downside, it seems like the week is one of sideways. There are still two trading days to make the week one of green […]
March 25th Biotech Update
Not much news this morning. The world is still here and while the stalemate continues in the Ukraine the lack of escalation probably keeps the market calm. There is still tremendous violence ongoing but at this point the market seems to have priced in the stalemate. I still think the stalemate breaks at some point […]
March 14th Biotech (and Ukraine) Update
Not much has changed in the Ukraine. This is probably a positive for the market but this stalemate cannot last indefinitely. If the Ukrainians are successfully hitting the Russian supply lines (as it appears) then the Russian forces will soon (another week or so) have very little supplies left that they will be unable to […]
Feb9th Biotech Update
The sector is doing well this week and hopefully we can keep it up. Not a lot of sector changing news but there is enough news that if one was looking for a reason to buy there are reasons. I still think it is less about the fundamentals at this point and more about the […]
February 4th Biotech Update
So we have not broken down which leaves the messy bottoming process still the potential pattern. Today will be sort of interesting from a market and sector perspective with the strong jobs report. The jobs report was unexpectedly strong and I assume that will increase rates and rate hike expectations. We know that the sector […]
January 28th Biotech Update
So it seems like the sector will not be building off of the reversals earlier in the week. We can point to a number of potential factors like the fed and interest rates, the correction in the broader markets, the risk of conflict in Europe, or the spate of clinical holds this week. I am […]
January 12th Biotech Update
I think the big news that was going to drop this week has dropped. There are still a lot of companies I am going to be following up with so there is still plenty to write about but I do not big new news coming. Given the lack of M&A and some negative news the […]
January 11th Biotech Update
I am a little surprised with the reversal yesterday. The lack of M&A and the news not being that great was setting the sector up to break to new lows. The fact that we were able to reverse is quite encouraging. Of course, we have all seen this picture before and we have routinely been […]
January 10th Biotech Update
Well, if you thought JPM 2021 was a disappointment you had not seen JPM 2022. While there can still be individual stock news I think the lack of any significant deals means that M&A is not going to be a theme in this conference. I guess the one advantage we have this year is that […]
January 7th Biotech Update
We should be in the calm before the storm as I do not see a company releasing news today. If you were going to announce something to get eyeballs before the conference then you more likely PRed earlier in the week. Releasing something Friday afternoon (outside of something bad to bury the news) does not […]
December 13th Biotech Update
We finally got a merger Monday and this should boost the sector. So far the sector is doing well in a generally bad market environment and hope this continues. There are certainly some non-sector related risks to the market that would hit biotech but as long as they remain muted, we should be able to […]
December 2nd Biotech Update
The sector is good at one thing and that is creating despair and frustration. The selloff has just been relentless and this is very much sentiment related. You can have relentless selling when fundamentals change, i.e. the energy sector at the start of the pandemic when the economy was shut down. There is nothing happening […]
November 19th Biotech Update
Guess what? We are stuck in a range and no one cares really about anything that happens in the sector. I grant that the news coming out of the sector this year has been pretty bad. The regulatory setbacks and clinical setbacks have been pretty non-stop. Add in the lack of a compelling drug launch […]
November 8th Biotech Update
We remain range bound with some weakness to end last week and some indecision to start this week. I still think we make a move to the upper end of this range at some point and I do not think the first attempt to breakout will be successful. It is possible but my running assumption […]
October 29th Biotech Update
It was a good day for the sector yesterday and with generally positive earnings there is a chance we could build some momentum. Add to that the removal of the drug pricing reform threat (it came out yesterday that was removed as a source of funding) and you have the potential to develop momentum. Of […]
